GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sio Gene Therapies Inc (OTCPK:SIOX) » Definitions » Revenue per Share

SIOX (Sio Gene Therapies) Revenue per Share : $0.00 (TTM As of Dec. 2022)


View and export this data going back to 2015. Start your Free Trial

What is Sio Gene Therapies Revenue per Share?

Sio Gene Therapies's revenue per share for the three months ended in Dec. 2022 was $0.00. Sio Gene Therapies's revenue per share for the trailing twelve months (TTM) ended in Dec. 2022 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Sio Gene Therapies's Revenue per Share or its related term are showing as below:

SIOX's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.5
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

Sio Gene Therapies Revenue per Share Historical Data

The historical data trend for Sio Gene Therapies's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sio Gene Therapies Revenue per Share Chart

Sio Gene Therapies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Revenue per Share
Get a 7-Day Free Trial - - - - -

Sio Gene Therapies Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sio Gene Therapies's Revenue per Share

For the Biotechnology subindustry, Sio Gene Therapies's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sio Gene Therapies's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sio Gene Therapies's PS Ratio distribution charts can be found below:

* The bar in red indicates where Sio Gene Therapies's PS Ratio falls into.



Sio Gene Therapies Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Sio Gene Therapies's Revenue Per Share for the fiscal year that ended in Mar. 2022 is calculated as

Revenue Per Share (A: Mar. 2022 )=Revenue (A: Mar. 2022 )/Shares Outstanding (Diluted Average) (A: Mar. 2022 )
=0/73.212
=0.00

Sio Gene Therapies's Revenue Per Share for the quarter that ended in Dec. 2022 is calculated as

Revenue Per Share (Q: Dec. 2022 )=Revenue (Q: Dec. 2022 )/Shares Outstanding (Diluted Average) (Q: Dec. 2022 )
=0/73.975
=0.00

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sio Gene Therapies  (OTCPK:SIOX) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Sio Gene Therapies Revenue per Share Related Terms

Thank you for viewing the detailed overview of Sio Gene Therapies's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Sio Gene Therapies Business Description

Traded in Other Exchanges
N/A
Address
130 West 42nd Street, 26th Floor, New York, NY, USA, 10036
Sio Gene Therapies Inc is a clinical-stage company that is focused on gene therapy for neurodegenerative diseases. The company is developing its pipeline for the treatment of debilitating diseases, including Parkinson's disease, GM1 gangliosidosis, and GM2 gangliosidosis.
Executives
Parag V Meswani officer: Chief Commercial Officer 130 WEST 42ND STREET, 26TH FLOOR, NEW YORK NY 10036
Pavan Cheruvu officer: Chief Executive Officer C/O AXOVANT SCIENCES, INC., 11 TIMES SQUARE, 33RD FLOOR, NEW YORK NY 10036
Atul Pande director C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Kristiina Md Vuori director C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Eric Venker director C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
David W. Nassif officer: Principal Financial Officer C/O STEADYMED THERAPEUTICS, INC., 2410 CAMINO RAMON, SAN RAMON CA 94583
Senthil Vel Sundaram director NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Dexxon Holdings Ltd. 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 30600000
Andrew Lo 10 percent owner C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
Svf Investments (uk) Ltd 10 percent owner 69 GROSVENOR STREET, LONDON X0 W1K3JP
Patrick Machado 10 percent owner 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Qvt Associates Gp Llc 10 percent owner 1177 AVENUE OF THE AMERICAS, 9TH FLOOR, NEW YORK NY 10036
Viking Global Performance Llc 10 percent owner 55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901

Sio Gene Therapies Headlines